P098 VISFATIN in bone metabolism of osteoporosis and osteoarthritis patients. (21st February 2018)

• Record Type: Journal Article
• Authors: Tsiklauri, L; Werner, J; Frommer, K; Engel, R; Rehart, S; Wenisch, S; Lange, U; Müller-Ladner, U; Neumann, E
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 1
• Page Start: A55
• Page End: A55
• Publication Date: 2018-02-21
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-EWRR2018.114
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Introduction: Osteoporosis predominantly affects elderly people and is characterised by bone loss, increased fracture risk and reduced regeneration ability. Age-related bone loss correlates with increased bone marrow adiposity due to a shift of osteogenic towards adipogenic differentiation of bone marrow-derived mesenchymal stem cells (MSC). Adipose tissue is metabolically active. Through the release of adipokines with immunomodulatory properties adipose tissue might influence differentiation of bone marrow-derived MSC and contribute to bone loss in osteoporosis. Objectives: Thus we analysed the presence of adipokines (visfatin, resistin and leptin) in the bone marrow cavity and their effects on MSC differentiation. Methods: MSC and RNA were isolated out of spongiosa from femoral heads (hip replacement surgery of osteoarthritis patients (OA) or after osteoporotic femoral neck fracture (FF). Adipogenic as well as osteogenic MSC differentiation was performed with/without adipokines. For the transfer and differentiation of MSC on cancellous bone, cell-free bone fragments were prepared and sterilised. Proinflammatory factors were measured by immunoassays. Gene expression was evaluated by Realtime PCR. Matrix mineralization was assayed using Alizarin red S staining. Results: While resistin was reduced, visfatin and leptin levels were increased in FF bone vs. non-osteoporotic OA bone (FF mean visfatin 7.77±1.86, n=11; OA 2.25±0.36, n=13, p=0.002). In contrast to leptin and resistin, visfatin induced the secretion of proinflammatory factors (IL-6, IL-8, MCP-1) during both, osteogenic and adipogenic differentiation, (e.g. adipogenic differentiation IL-6, 21d; control: 270.3±140.2 pg/ml; visfatin: 3, 223±600.4 pg/ml, p=0.0006, n=12). In osteogenically differentiated cells matrix mineralization was significantly increased, while collagen type 1 expression was downregulated (d21: −4.2-fold/p=0.0001; n=7) after visfatin stimulation. The expression of MMP2, −13, TIMP1 and −2 (e.g. d21: −2.4-fold; −3.2-fold; −3.2-fold; −4.3 fold, respectively) was also reduced by visfatin during osteogenesis. Interestingly, visfatin significantly induced MMP13 expression (e.g. d21: 104-fold) during adipogenic differentiation under cell culture conditions. However, when differentiated on autologous cancellous bone, visfatin-induced MMP13 expression, as well as IL-6 and IL-8 release was markedly reduced (e.g. MMP13 21d: 13.8-fold, p=0.0156, n=7). Conclusions: Taken together, visfatin expression was not only elevated in osteoporotic bone, it induced release of proinflammatory factors and dysregulated the MMP/TIMP balance during MSC-differentiation. Therefore visfatin might influence bone remodelling specifically at the bone/adipose tissue interface. The visfatin-mediated increase of matrix mineralization and the observed reduction of organic component of ECM – Coll.1, essential for the bone plasticity might contribute to bone fragility and therefore to the pathogenesis of osteoporosis. Disclosure of interest: None declared